MAGIC in practice: Experience of peri‐operative ECF/X chemotherapy in gastro‐esophageal adenocarcinomas

Abstract

Our patient population is older than the patients in the MAGIC trial (age 66 years vs. 62 years) with a much higher proportion of esophageal and GEJ tumours. Overall, curative resection rate was comparable to the MAGIC trial. Overall survival is superior to that found in the MAGIC trial.